Tags

Type your tag names separated by a space and hit enter

Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
Neuroimage Clin 2018; 19:190-201NC

Abstract

Alzheimer's disease (AD) is characterized by an accumulation of β-amyloid (Aβ42) accompanied by brain atrophy and cognitive decline. Several recent studies have shown that Aβ42 accumulation is associated with gray matter (GM) changes prior to the development of cognitive impairment, in the so-called preclinical stage of the AD (pre-AD). It also has been proved that the GM atrophy profile is not linear, both in normal ageing but, especially, on AD. However, several other factors may influence this association and may have an impact on the generalization of results from different samples. In this work, we estimate differences in rates of GM volume change in cognitively healthy elders in association with baseline core cerebrospinal fluid (CSF) AD biomarkers, and assess to what these differences are sample dependent. We report the dependence of atrophy rates, measured in a two-year interval, on Aβ42, computed both over continuous and categorical values of Aβ42, at voxel-level (p < 0.001; k < 100) and corrected for sex, age and education. Analyses were performed jointly and separately, on two samples. The first sample was formed of 31 individuals (22 Ctrl and 9 pre-AD), aged 60-80 and recruited at the Hospital Clinic of Barcelona. The second sample was a replica of the first one with subjects selected from the ADNI dataset. We also investigated the dependence of the GM atrophy rate on the basal levels of continuous p-tau and on the p-tau/Aβ42 ratio. Correlation analyses on the whole sample showed a dependence of GM atrophy rates on Aβ42 in medial and orbital frontal, precuneus, cingulate, medial temporal regions and cerebellum. Correlations with p-tau were located in the left hippocampus, parahippocampus and striatal nuclei whereas correlation with p-tau/Aβ42 was mainly found in ventral and medial temporal areas. Regarding analyses performed separately, we found a substantial discrepancy of results between samples, illustrating the complexities of comparing two independent datasets even when using the same inclusion criteria. Such discrepancies may lead to significant differences in the sample size needed to detect a particular reduction on cerebral atrophy rates in prevention trials. Higher cognitive reserve and more advanced pathological progression in the ADNI sample could partially account for the observed discrepancies. Taken together, our findings in these two samples highlight the importance of comparing and merging independent datasets to draw more robust and generalizable conclusions on the structural changes in the preclinical stages of AD.

Authors+Show Affiliations

Barcelonaβeta Brain Research Center, Pasqual Maragall Foundation, Barcelona, Spain; CIBER-BBN, Madrid, Spain.Barcelonaβeta Brain Research Center, Pasqual Maragall Foundation, Barcelona, Spain.Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.Barcelonaβeta Brain Research Center, Pasqual Maragall Foundation, Barcelona, Spain.Barcelonaβeta Brain Research Center, Pasqual Maragall Foundation, Barcelona, Spain.Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Neurology Department, Hospital Clínic i Provincial de Barcelona, Barcelona, Spain.Barcelonaβeta Brain Research Center, Pasqual Maragall Foundation, Barcelona, Spain; CIBER-BBN, Madrid, Spain. Electronic address: jdgispert@barcelobabeta.org.Barcelonaβeta Brain Research Center, Pasqual Maragall Foundation, Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Neurology Department, Hospital Clínic i Provincial de Barcelona, Barcelona, Spain; CIBER Fragilidad y Envejecimiento Saludable (CIBERFES), Madrid, Spain. Electronic address: jlmolinuevo@barcelonabeta.org.No affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

30023169

Citation

Falcon, Carles, et al. "Longitudinal Structural Cerebral Changes Related to Core CSF Biomarkers in Preclinical Alzheimer's Disease: a Study of Two Independent Datasets." NeuroImage. Clinical, vol. 19, 2018, pp. 190-201.
Falcon C, Tucholka A, Monté-Rubio GC, et al. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets. Neuroimage Clin. 2018;19:190-201.
Falcon, C., Tucholka, A., Monté-Rubio, G. C., Cacciaglia, R., Operto, G., Rami, L., ... Molinuevo, J. L. (2018). Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets. NeuroImage. Clinical, 19, pp. 190-201. doi:10.1016/j.nicl.2018.04.016.
Falcon C, et al. Longitudinal Structural Cerebral Changes Related to Core CSF Biomarkers in Preclinical Alzheimer's Disease: a Study of Two Independent Datasets. Neuroimage Clin. 2018;19:190-201. PubMed PMID: 30023169.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets. AU - Falcon,Carles, AU - Tucholka,Alan, AU - Monté-Rubio,Gemma C, AU - Cacciaglia,Raffaele, AU - Operto,Grégory, AU - Rami,Lorena, AU - Gispert,Juan Domingo, AU - Molinuevo,José Luis, AU - ,, Y1 - 2018/04/16/ PY - 2017/12/22/received PY - 2018/03/08/revised PY - 2018/04/14/accepted PY - 2018/7/20/entrez PY - 2018/7/20/pubmed PY - 2019/1/16/medline KW - AD, Alzheimer's disease KW - ADNI, Alzheimer's Disease Neuroimaging Initiative KW - Alzheimer's disease KW - Aβ42, amyloid beta KW - CDR, Clinical Dementia Rating KW - CSF biomarkers KW - CSF, Cerebro-Spinal Fluid KW - Ctrl, control KW - DI, divergences of the longitudinal deformations KW - ELISA, Enzyme-Linked ImmunoSorbent Assay KW - FWE, Family Wise Error KW - GM, gray matter KW - HCB, Hospital Clinic Barcelona KW - L, left KW - Longitudinal VBM KW - MMSE, Mini Mental State examination KW - PLR, pairwise longitudinal registration KW - Preclinical Alzheimer's disease KW - R, right KW - ROI, region of interest KW - TIV, total intracranial volume KW - VBM, voxel-based morphometry KW - WM, white matter KW - p-tau, phosphorylated tau KW - preAD, preclinical Alzheimer's disease KW - t-tau, total tau SP - 190 EP - 201 JF - NeuroImage. Clinical JO - Neuroimage Clin VL - 19 N2 - Alzheimer's disease (AD) is characterized by an accumulation of β-amyloid (Aβ42) accompanied by brain atrophy and cognitive decline. Several recent studies have shown that Aβ42 accumulation is associated with gray matter (GM) changes prior to the development of cognitive impairment, in the so-called preclinical stage of the AD (pre-AD). It also has been proved that the GM atrophy profile is not linear, both in normal ageing but, especially, on AD. However, several other factors may influence this association and may have an impact on the generalization of results from different samples. In this work, we estimate differences in rates of GM volume change in cognitively healthy elders in association with baseline core cerebrospinal fluid (CSF) AD biomarkers, and assess to what these differences are sample dependent. We report the dependence of atrophy rates, measured in a two-year interval, on Aβ42, computed both over continuous and categorical values of Aβ42, at voxel-level (p < 0.001; k < 100) and corrected for sex, age and education. Analyses were performed jointly and separately, on two samples. The first sample was formed of 31 individuals (22 Ctrl and 9 pre-AD), aged 60-80 and recruited at the Hospital Clinic of Barcelona. The second sample was a replica of the first one with subjects selected from the ADNI dataset. We also investigated the dependence of the GM atrophy rate on the basal levels of continuous p-tau and on the p-tau/Aβ42 ratio. Correlation analyses on the whole sample showed a dependence of GM atrophy rates on Aβ42 in medial and orbital frontal, precuneus, cingulate, medial temporal regions and cerebellum. Correlations with p-tau were located in the left hippocampus, parahippocampus and striatal nuclei whereas correlation with p-tau/Aβ42 was mainly found in ventral and medial temporal areas. Regarding analyses performed separately, we found a substantial discrepancy of results between samples, illustrating the complexities of comparing two independent datasets even when using the same inclusion criteria. Such discrepancies may lead to significant differences in the sample size needed to detect a particular reduction on cerebral atrophy rates in prevention trials. Higher cognitive reserve and more advanced pathological progression in the ADNI sample could partially account for the observed discrepancies. Taken together, our findings in these two samples highlight the importance of comparing and merging independent datasets to draw more robust and generalizable conclusions on the structural changes in the preclinical stages of AD. SN - 2213-1582 UR - https://www.unboundmedicine.com/medline/citation/30023169/Longitudinal_structural_cerebral_changes_related_to_core_CSF_biomarkers_in_preclinical_Alzheimer's_disease:_A_study_of_two_independent_datasets_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S2213-1582(18)30125-6 DB - PRIME DP - Unbound Medicine ER -